[Advances in the treatment of the galactorrhoea-amenorrhoea-syndrome: Induction of ovulation and inhibition of lactation with 2-Br-alpha-ergo-cryptine (author's transl)].
D000284:Administration, Oral; D000328:Adult; D000568:Amenorrhea / Q000139:chemically induced / Q000188:drug therapy*; D001966:Bromine / Q000627:therapeutic use; D002640:Chiari-Frommel Syndrome / Q000188:drug therapy; D003276:Contraceptives, Oral / Q000009:adverse effects; D004876:Ergot Alkaloids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007775:Lactation Disorders / Q000139:chemically induced / Q000188:drug therapy*; D010060:Ovulation; D011247:Pregnancy; D011388:Prolactin / Q000037:antagonists & inhibitors*; D013577:Syndrome
D003276:Contraceptives, Oral; D004876:Ergot Alkaloids; D011388:Prolactin; D001966:Bromine
Fortschritt in der Behandlung des Galaktorrhoe-Amenorrhoe-Syndroms: Ovulationsauslösung und Hemmung der Milchsekretion mit 2-Br-alpha-Ergokryptin.